Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:11 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Endovascular Stroke Treatment And Reteplase Protocol
NCT05900674 · Zeenat Qureshi Stroke Institute · PHASE2 · withdrawn · last registry update 2024-04-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor” | – | Registry record, Zeenat Qureshi Stroke Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PLAT within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-04-02Results posted on the registry: Supergene, LLC, Recombinant staphylokinase + Alteplase (NCT03151993)
- 2025-04-02Results posted on the registry: Supergene, LLC, Recombinant nonimmunogenic staphylokinase + Alteplase (NCT04688320)
- 2025-03-20Results posted on the registry: Supergene, LLC, Recombinant staphylokinase + Tenecteplase (NCT02301910)
- 2025-03-14Phase 3 first posted: Guri Hagberg, thrombolysis therapy (NCT06878066)
- 2025-03-11Phase 3 first posted: Beijing Tiantan Hospital, Standard medical treatment (NCT06868511)
- 2025-03-03Also stopped (terminated): Haukeland University Hospital, Tenecteplase + Alteplase (NCT03854500)
- 2025-02-24Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Intravenous thrombolysis (NCT06841965)
- 2025-02-24Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Intravenous Thrombolysis (NCT06841978)
- 2025-02-21Also stopped (withdrawn): Prisma Health-Midlands, early tPA and DNase (NCT03167281)
- 2025-01-31Results posted on the registry: University of Calgary, Tenecteplase + Antiplatelet treatment (NCT02398656)
- 2025-01-15Also stopped (terminated): University of Melbourne, Tenecteplase + Standard Care (which may include intravenous Alteplase) (NCT04454788)
- 2025-01-10Phase 3 first posted: Central Hospital, Nancy, France, Intra-arterial infusion of Alteplase (NCT06768138)
- 2024-12-27Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Intravenous thrombolysis (NCT06749834)
- 2024-12-11Results posted on the registry: Memorial Healthcare System, Cathflo Activase + Talc Slurry Pleurodesis (NCT04806373)
- 2024-12-10Results posted on the registry: Boehringer Ingelheim, tenecteplase + alteplase (NCT04915729)
- 2024-10-28Phase 3 first posted: Shin Poong Pharmaceutical Co. Ltd., SP-8203 + Placebo (NCT06660719)
- 2024-10-26Phase 3 first posted: Xuanwu Hospital, Beijing, Tenecteplase + Alteplase (NCT06658197)
- 2024-10-22Results posted on the registry: Wake Forest University Health Sciences, Tranexamic acid + Epsilon Aminocaproic Acid (NCT02656472)
- 2024-10-16Also stopped (withdrawn): Wake Forest University Health Sciences, Tenecteplase (NCT00431379)
- 2024-10-04Results posted on the registry: KU Leuven, Tenecteplase + Clopidogrel (NCT02777580)
- 2024-10-01Also stopped (withdrawn): ZZ Biotech, LLC, 3K3A-APC (NCT05484154)
- 2024-09-19Also stopped (suspended): Centre hospitalier de l'Université de Montréal (CHUM), Best standard treatment (NCT02157532)
- 2024-08-23Results posted on the registry: Chiesi Farmaceutici S.p.A., CUSA-081 + Placebo (NCT03594175)
- 2024-08-23Also stopped (terminated): Chiesi Farmaceutici S.p.A., CUSA-081 + Placebo (NCT03594175)
- 2024-06-26Results posted on the registry: NYU Langone Health, Tranexamic acid + Aminocaproic acid (NCT04814433)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision